
    
      This multicenter, non-comparative phase IV clinical trial will be conducted at brazilian
      clinical trial centers under the auspices of Eurofarma Laboratories S.A. Recruitment for the
      study will begin after the relevant ethical and regulatory approvals and will have an
      estimated duration of 4 months.

      The study will include 80 female participants aged between 45 and 60 years and menopausal
      memory complaints who consent to participate in the study by signing the informed consent
      form.

      To be included, participants must meet all inclusion criteria and none of the exclusion
      criteria. Each participant will initially complete a selection period with a maximum duration
      of 14 days for evaluation of eligibility. Participants will then be treated with CogmaxÂ® in
      the dosage of two capsules per day for 12 weeks.
    
  